glp-1 asa medications safe to continue before surgery in patients with diabetes and obesity Less than half of Brits

Combination therapy with liraglutide yielded greater HbA1c and weight reductions compared to dulaglutide

But no research has examined the difference between single-agonist (semaglutide) and dual-agonist (tirzepatide) approaches specifically for endometriosis outcomes

Insulin drugs and GLP-1 receptor agonists are utilized as crucial therapeutic options in diabetes management and obesity treatment throughout Europe

Most GLP-1 agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) do not require dose adjustment for mild-to-moderate renal impairment, though caution is warranted in severe renal impairment

Li X-X, Zhang X-X, Zhang R, Ni Z-J, Elam E, Thakur K, Cespedes-Acua CL, Zhang J-G, Wei Z-J